Biophage Pharma Inc. Announces Commercial Launch of Titanium Hypersensitivity Detection Test at Mini Symposium on the Effect of Toxic Metals and Nanoparticles on Human Health

Published: Dec 06, 2007

MONTREAL, Dec. 6 /CNW Telbec/ - (TSX.V: BUG) - Biophage Pharma is very pleased to announce today the commercial launch of a new test for the detection of titanium hypersensitivity during a mini symposium held in Montreal on the effect of toxic metals and nanoparticles on human health. Co-hosted by Biophage Pharma and the MELISA(R) Foundation, this Mini Symposium was presented by Professor Vera Stejskal, inventor of the MELISA(R) technology. Invited guests were given a tour of Biophage ImmunotoxLabs and were able to interact with its scientists.

Back to news